Cerebral Amyloid AngiopathySymptoms, Doctors, Treatments, Advances & More
Learn About Cerebral Amyloid Angiopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Vanderbilt Medical Group- Teleneurology
Matthew Schrag is a Neurologist practicing medicine in Nashville, Tennessee. Dr. Schrag is rated as an Elite provider by MediFind in the treatment of Cerebral Amyloid Angiopathy. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Cerebral Amyloid Angiopathy, Stroke, Hereditary Cerebral Amyloid Angiopathy, Thrombectomy, and Gastrostomy. Dr. Schrag is board certified in American Board Of Psychiatry & Neurology.
Gregoire Boulouis practices practicing medicine in Tours, France. Mr. Boulouis is rated as an Elite expert by MediFind in the treatment of Cerebral Amyloid Angiopathy. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Cerebral Amyloid Angiopathy, Siderosis, Stroke, Thrombectomy, and Stent Placement.
Nicolas Raposo practices practicing medicine in Toulouse, France. Mr. Raposo is rated as an Elite expert by MediFind in the treatment of Cerebral Amyloid Angiopathy. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Cerebral Amyloid Angiopathy, Siderosis, Primary Amyloidosis, Thrombectomy, and Craniectomy.
Summary: The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. ...
Summary: The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid angiopathy, including adults of both sexes. The main questions it aims to answer is: how is the patients' experience regarding the use of the STRATIF-AI platform? Researchers ...